Blog Full Right Sidebar

With Frame
According to sources familiar with the matter, the Securities and Exchange Board of India has held back its green light for the much-awaited public issues so far, as share sales by these companies could have inadvertently ended up violating rules that govern unlisted companies.
Read More
Zydus Lifesciences said it has received final approval from the US health regulator to manufacture a generic version of Apalutamide tablets used in the treatment of prostate cancer
Read More
Analysts expect the market recovery to continue in the near term on the back of positive global cues and value buying at lower levels.
Read More
The NSE Nifty surged 325.55 points, or 1.45%, to close at 22,834.30. The BSE Sensex rose 1131.31 points, or 1.53%, to end at 75,301.26. Both indices have risen about 2% in the last two days.
Read More
IndusInd Bank promoters reaffirm their commitment to the bank, viewing its depressed stock value as a strategic investment opportunity. Despite a 50% drop in six months, no fresh capital infusion is required. Hinduja Group holds a 16.29% stake, with 50.8% pledged.
Read More
1 13 14 15 16 17 40

Text Widget

Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Nulla vitae elit libero, a pharetra augue. Donec sed odio dui. Etiam porta sem malesuada.

Recent News

Stocks to Buy | Dipan Mehta’s top stock picks & sectors to watch for big gains!
March 19, 2025
Explainer: How accounting mismatches created a Rs 1,500 cr crisis at IndusInd Bank
March 19, 2025
Can 23,050 level unlock a new high for Nifty? Rohit Srivastava answers
March 19, 2025

Recent Cases